| The global metabolic syndrome market amounts to a total share of US $ 72.3 billion that is further predicted to reach US $ 96.4 billion in the year 2011. The current growth rate of this industry is 5.9%. A study conducted in USA reports that around 25 percent i.e. 47 million of US residents are affected by metabolic syndrome. Anti platelet, anti inflammatory, anti hypertensive, cholesterol, and blood glucose medications are mostly prescribed specifically for treating the metabolic syndrome. Through metabolic drugs, a wide variety of diseases can be treated like diabetes, central nervous system disorders, obesity, hyperlipidemia, hypertension, glucose intolerance, heart diseases etc.